Association of Immunohistochemical Expression of  P53 in Pancreatic Ductal Adenocarcinoma

Hassan  Tariq; Amna  Ameer; Wajahat Ahmed Khan; Syed Rehan Asghar  Naqvi; Saba  Rizwan; Saba  Humayun

doi:10.51253/pafmj.v75i3.10507

Authors

Hassan Tariq Department of Histopathology, Armed Forces Institute of Pathology, Rawalpindi/National University of Medical Sciences (NUMS) Pakistan
Amna Ameer Department of Histopathology, Armed Forces Institute of Pathology, Rawalpindi/National University of Medical Sciences (NUMS) Pakistan
Wajahat Ahmed Khan Department of Histopathology, Armed Forces Institute of Pathology, Rawalpindi/National University of Medical Sciences (NUMS) Pakistan
Syed Rehan Asghar Naqvi Department of Histopathology, Armed Forces Institute of Pathology, Rawalpindi/National University of Medical Sciences (NUMS) Pakistan
Saba Rizwan Department of Histopathology, Armed Forces Institute of Pathology, Rawalpindi/National University of Medical Sciences (NUMS) Pakistan
Saba Humayun Department of Histopathology, Armed Forces Institute of Pathology, Rawalpindi/National University of Medical Sciences (NUMS) Pakistan

DOI:

https://doi.org/10.51253/pafmj.v75i3.10507

Keywords:

Adenocarcinoma pancreas, Chronic pancreatitis. P53 immunohistochemistry

Abstract

Objective: To assess the immunohistochemical expression of p53 in pancreatic ductal adenocarcinoma and chronic pancreatitis.

Study Design: Comparative cross-sectional study.

Place and Duration of Study: Department of Histopathology, Armed Forces Institute of Pathology, Rawalpindi, Pakistan from Jul 2020 to Jun 2022.

Methodology: Our study inducted 116 individuals in total (56 with cancer and 60 with pancreatitis). Following the recovery of the cases, each block was divided into sections and stained with hematoxylin-eosin and p53 antibodies. Microsoft Excel 2010 was used for the statistical analysis.

Results: Out of the 116 cases studied, 56 cases were found to be adenocarcinoma. Among these cases, 42(75%) showed p53 positivity according to the Sophia scoring system, with +3 and +4 staining considered positive. Of these 56 cases, 3 cases were scored 1+, 11 cases were scored 2+, 21 cases were scored 3+, and 21 cases were scored 4+. 8 out of 60 cases (13.33%) of pancreatitis showed p53 positivity.

Conclusion: The majority of pancreatic adenocarcinomas exhibit immunohistochemical overexpression of p53, which can be used in conjunction with other immunohistochemical markers to aid in the diagnosis of carcinoma and differentiate it from benign mimickers.

Downloads

Download data is not yet available.

References

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68(6): 394-424.

https://doi.org/10.3322/caac.21492

Miller KD, Siegel RL, Lin CC, Mariotto AB, Kramer JL, Rowland JH, et al. Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin 2016; 66(4): 271-289.

https://doi.org/10.3322/caac.21349

Pourhoseingholi MA, Ashtari S, Hajizadeh N, Fazeli Z, Zali MR. Systematic review of pancreatic cancer epidemiology in Asia-Pacific Region: major patterns in GLOBACON 2012. Gastroenterol Hepatol Bed Bench 2017; 10(4): 245-257.

Neoptolemos JP, Springfeld C, Hackert T. A Review of Pancreatic Cancer. JAMA 2021; 326(23): 2436.

https://doi.org/10.1001/jama.2021.20065

Cao W, Chen HD, Yu YW, Li N, Chen WQ. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020. Chin Med J 2021; 134(7): 783-791. https://doi.org/10.1097/CM9.0000000000001474

Abbas G, Shah S, Hanif M, Asghar A, Shafique M, Ashraf K et al. Cancer prevalence, incidence and mortality rates in Pakistan in 2018. Bull Cancer 2020; 107(4): 517-518.

https://doi.org/10.1016/j.bulcan.2019.12.011

Ali SM, Adnan Y, Ali SA. Pancreatic Cancers: A Review of Studies from Pakistan and Comparison with Global Trends. Pak J Public Health 2021; 11(2): 120-127.

Ahmad Z, Din NU, Minhas K, Moeen S, Ahmed A. Epidemiologic Data, Tumor Size, Histologic Tumor Type and Grade, Pathologic Staging and Follow Up in Cancers of the Ampullary Region and Head of Pancreas in 311 Whipple Resection Specimens of Pakistani Patients. Asian Pac J Cancer Prev 2015; 16(17): 7541-7546.

https://doi.org/10.7314/apjcp.2015.16.17.7541

Hidalgo M, Cascinu S, Kleeff J, Labianca R, Löhr JM, Neoptolemos J, et al. Addressing the challenges of pancreatic cancer: future directions for improving outcomes. Pancreatology 2015; 15(1): 8-18.

https://doi.org/10.1016/j.pan.2014.10.001

Voutsadakis IA. Mutations of p53 associated with pancreatic cancer and therapeutic implications. Ann Hepatobiliary Pancreat Surg 2021; 25(3): 315-327.

https://doi.org/10.14701/ahbps.2021.25.3.315

Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 2013; 6(269): pl1. https://doi.org/10.1126/scisignal.2004088

Ameer EA, Ghafour KH. Expression of p53 in Pancreatic Ductal Adenocarcinoma. Iraqi Postgrad Med J 2022; 21(2).

Qin LX, Tang ZY, Ma ZC, Wu ZQ, Zhou XD, Ye QH, et al. P53 immunohistochemical scoring: an independent prognostic marker for patients after hepatocellular carcinoma resection. World J Gastroenterol 2002; 8(3): 459-463.

https://doi.org/10.3748/wjg.v8.i3.459

Cruz I, Snijders PJ, Van Houten V, Vosjan M, Van der Waal I, Meijer CJ. Specific p53 immunostaining patterns are associated with smoking habits in patients with oral squamous cell carcinomas. J Clin Pathol 2002; 55(11): 834-40.

https://doi.org/10.1136/jcp.55.11.834

Cho J, Petrov MS. Pancreatitis, Pancreatic Cancer, and Their Metabolic Sequelae: Projected Burden to 2050. Clin Transl Gastroenterol 2020; 11(11): e00251.

https://doi.org/10.14309/ctg.0000000000000251

Capasso M, Franceschi M, Rodriguez-Castro KI, Crafa P, Cambiè G, Miraglia C, et al. Epidemiology and risk factors of pancreatic cancer. Acta Biomed 2018; 89(9-S): 141-146. https://doi.org/10.23750/abm.v89i9-S.7923

Cicenas J, Kvederaviciute K, Meskinyte I, Meskinyte-Kausiliene E, Skeberdyte A, Cicenas J et al. KRAS, TP53, CDKN2A, SMAD4, BRCA1, and BRCA2 Mutations in Pancreatic Cancer. Cancers 2017; 9(5): 42.

https://doi.org/10.3390/cancers9050042

Kern SE, Pietenpol JA, Thiagalingam S, Seymour A, Kinzler KW, Vogelstein B et al. Oncogenic forms of p53 inhibit p53-regulated gene expression. Science 1992; 256(5058): 827-830.

https://doi.org/10.1126/science.1589764

Hwang RF, Gordon EM, Anderson WF, Parekh D. Gene therapy for primary and metastatic pancreatic cancer with intraperitoneal retroviral vector bearing the wild-type p53 gene. Surgery 1998; 124(2): 143-150.

Morton JP, Timpson P, Karim SA, Ridgway RA, Athineos D, Doyle B, et al. Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer. Proc Natl Acad Sci U S A 2010; 107(1): 246-251.

https://doi.org/10.1073/pnas.0908428107

Zhao H, Wang Q, Wang X, Zhu H, Zhang S, Wang W, et al. Correlation Between RAB27B and p53 Expression and Overall Survival in Pancreatic Cancer. Pancreas 2016; 45(2): 204-210.

https://doi.org/10.1097/MPA.0000000000000453

Apple SK, Hecht JR, Lewin DN, Jahromi SA, Grody WW, Nieberg RK. Immunohistochemical evaluation of K-ras, p53, and HER-2/neu expression in hyperplastic, dysplastic, and carcinomatous lesions of the pancreas: evidence for multistep carcinogenesis. Hum Pathol 1999; 30(2): 123-129.

https://doi.org/10.1016/s0046-8177(99)90265-4

DiGiuseppe JA, Hruban RH, Goodman SN, Polak M, van den Berg FM, Allison DC et al. Overexpression of p53 protein in adenocarcinoma of the pancreas. Am J Clin Pathol 1994; 101(6): 684-688.

https://doi.org/10.1093/ajcp/101.6.684

Slebos RJ, Hoppin JA, Tolbert PE, Holly EA, Brock JW, Zhang RH, et al. K-ras and p53 in pancreatic cancer: association with medical history, histopathology, and environmental exposures in a population-based study. Cancer Epidemiol Biomarkers Prev 2000; 9(11): 1223-1232.

Blanck HM, Tolbert PE, Hoppin JA. Patterns of genetic alterations in pancreatic cancer: a pooled analysis. Environ Mol Mutagen 1999; 33(2): 111-122.

https://doi.org/10.1002/(sici)1098-2280